Samsung Biologics Earns Top Rating in Water Security from CDP Evaluation

Proving Global Leadership in Transparency and Execution
Just Two Years After Joining the Evaluation

Samsung Biologics announced on December 11 that it has received the highest grade, 'A', in the Water Security category from the Carbon Disclosure Project (CDP), a global sustainability assessment organization. This marks an improvement from last year's A- grade.

Samsung Biologics was selected as an 'A-List' company after earning the top A grade in the Water Security category for the first time, just two years after participating in the CDP assessment. The A-List comprises leading companies that have received the highest ratings in each field, officially recognizing their global leadership in transparency and execution. Typically, only about 2% of companies participating in the CDP assessment are included in the A-List.

Samsung Biologics Plant 4 Overview. Samsung Biologics

Since its establishment in the United Kingdom in 2000, CDP has been conducting a project requesting information disclosure on environmental issues from major listed companies worldwide. Leading global pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca (AZ), and Novartis, along with investors, actively encourage participation in the CDP assessment to evaluate companies’ responses to climate change. To receive a high rating, companies must achieve consistently high scores across various areas such as strategy, targets, and activities, which significantly enhances their external reputation.

In this assessment, Samsung Biologics was recognized for its outstanding ESG (Environmental, Social, and Governance) capabilities through activities such as establishing concrete targets for natural capital strategy and water pollution management, improving water reuse rates, and ensuring the accuracy and reliability of water intake, discharge, and consumption data.

Furthermore, Samsung Biologics has been focusing its company-wide capabilities on ESG management, aiming to be a sustainable Contract Development and Manufacturing Organization (CDMO) partner. In the globally significant Sustainable Markets Initiative (SMI), John Rim, CEO of Samsung Biologics, serves as the chair of the supply chain sector in the Health Systems Task Force, thereby strengthening the company's global leadership in ESG. SMI is a global climate change response initiative launched under the patronage of King Charles III of the United Kingdom following the World Economic Forum (WEF) in 2020.

Recognized for its efforts toward a sustainable future, Samsung Biologics was also awarded the SMI's 'Terra Carta Seal' in 2023, which is granted only to companies that present concrete and innovative roadmaps for achieving carbon neutrality.

CEO Rim stated, "This assessment is the result of faithfully implementing activities that meet the ESG environmental strategies required by global clients," adding, "Samsung Biologics will continue its efforts to achieve carbon neutrality and strengthen water resource management."

This content was produced with the assistance of AI translation services.